Mara Hollis

A COA counts only if the lab's own lookup returns the same report. Nine labs with public lookups, the six-field check we run on 2,490 mirrored certificates, and the signs of a recycled PDF.

HHS says it will not act against 503A pharmacies compounding BPC-157, TB-500, epitalon, KPV, MOTS-c or semax under ten conditions. Research vials are not covered.

Peptide prices on 21 October 2026: retatrutide $6.50/mg, BPC-157 $6.12, TB-500 $7.03, GHK-Cu $0.79. Medians from 128 listings at 9 vendors, and the gaps.

Between February and April 2026 one sponsor registered eight trials for BPC-157, TB-500, GHK-Cu, MOTS-c, Melanotan II, tesamorelin, tirzepatide and retatrutide. One record calls itself fictional, one is titled a mock study, one calls itself an example record, and one copies Lilly's SURMOUNT-1 down to the protocol code. An NCT number is not evidence that a trial exists.

On 18 September 2026 a federal jury convicted the owner of Pinned Aminos. The site said research use only and the labels said not for human consumption, while the sellers posted dosing directions in a private Facebook group. Prosecutors argued the disclaimer existed to mislead FDA, and the jury agreed.

Phenibut is not a federal controlled substance, but the FDA says it is not a lawful dietary ingredient, so it cannot be sold as a supplement. A handful of states restrict it, and it carries a real dependence and withdrawal risk.

Tianeptine is not FDA-approved and is sold gray-market as 'gas station heroin.' It is not a federal controlled substance yet, but FDA import-alerts it, warns consumers against it, and a growing list of states have banned or scheduled it.

Eli Lilly sued American Peptides LLC in Louisiana federal court on 8 Oct 2026. The complaint is public since 26 Oct. Which site, the 100/100 rating, what's next.

Federal agents searched an address listed for Apex Peptides on 23 Sep 2026. No charges by 10 Oct. Which Apex sites are live, and what to do about an order.

Nexaph, EZ Peptides and Ameano show one SS-31 analysis on Janoshik tasks 163730-163732. Finnrick gives Nexaph a 60% pass rate. What the record shows.

CBP told the WSJ of 2,400+ drug-product seizures from Oct 2025 to Aug 2026. What a seizure notice means, and what a US warehouse does not change.

FDA has sent 22 warning letters citing retatrutide since Dec 2024. On 10 Oct 2026, six of the named sites still listed it with a cart button.

Lilly has filed 11 retatrutide suits since August 2026; three have ended and eight are open. Lilly says Texas Peptides settled. The dockets and evidence.

Nine peptide vendors pitched us between 4 Sep and 7 Oct 2026. The top offer was 40% of every order. We are taking one, at 10%. The checks behind each call.

FDA sent five peptide warning letters dated 24 Aug 2026; Lilly sued six retatrutide sellers on 12 Aug. Code names, bac water and calculators were evidence.

Janoshik's GLP-1 test is $360; Finnrick's original COAs now need a $9.99/mo membership. Eight labs on price, identity method and how to verify.

Retatrutide price per month: the 12 mg TRIUMPH arm used 48 mg per 4 weeks, $168 to $626 at 21 October 2026 gray-market prices (median $312).

PCAC backed 6 of 7 peptides in July. On 28 Oct HHS filed an interim compounding policy for all six. It is not a rule and does not cover research vials.

FDA's 2026-08-24 letters name 'GLP-3 RT', 'GLP-3R' and 'GLP-3 Reta' as retatrutide. Alias table with COA purity per code name.

Five 503A telehealth compounders audited under the same rubric - Trillium, Fifty410, Hims, Henry Meds, Mochi Health. Mochi leads on prescriber transparency (board-certified obesity-medicine physicians). Fifty410 leads on regulatory cleanliness. The full cohort comparison, scored.

They're not really "versus" - the two compounds work through different receptors and synergize. CJC-1295 hits the GHRH receptor; ipamorelin hits the ghrelin receptor. The stack is research-protocol canon. Here's the actual breakdown plus the comparison framing most buyers want.

Two repurposed drugs studied for longevity, two different mechanisms, two different evidence bases. Rapamycin has the strongest cross-species lifespan-extension data in pharmacology. Metformin has 60+ years of human safety data and the active TAME trial. The honest comparison.

Both are GHRH analogs. Tesamorelin is FDA-approved as Egrifta; sermorelin's Geref approvals were withdrawn in 2009 for commercial reasons. How they differ.

SURMOUNT-5 (NEJM 2025, 751 adults, 72 weeks): tirzepatide cut weight 20.2% vs 13.7% on semaglutide. Dual GLP-1/GIP vs GLP-1 only, side effects and cost.

All five FDA peptide letters of 2026-08-24 cite bac water; four list it as an unapproved drug. Shelf life after opening, sterile water, supply status.

GLP-1 receptor agonists cause weight loss that is between 25% and 40% lean mass by default. Resistance training and protein intake shift that ratio. Here's the trial data and the protocol levers that actually move it.

The same operation now runs under two domains. The legacy site is still live, the new domain inherits the old contact infrastructure, and the Trustpilot review base was seeded via a promo-code review program. Here's the buyer-relevant breakdown.

We applied a 10-signal hostname-aliasing check to 32 research-peptide vendor domains. Multiple confirmed alias clusters surfaced, including a smoking-gun shared Google Tag Manager ID linking three "different" peptide brands to one operator.

FDA's August 2026 letters quoted GLP-1 S, GLP-2 TRZ, GLP-3 Reta and BIMORELIN by name. A code name stopped none of them. Decoder table.

Some research-peptide brands aren't separate vendors — they're hostname aliases pointing at a shared backend. Here's how to detect the pattern in under sixty seconds, with a worked example from our own audit cohort.

When two 'different' peptide vendors cite the exact same Janoshik test URL for the same product batch, they're sourcing from the same upstream manufacturer. We documented this pattern between Summit Biotech and the Peptopia community-tracker batches — confirming Geneza Pharmaceuticals as the shared upstream.

Four structural drivers behind peptide-vendor alias clusters — payment-processor mortality, FDA enforcement, community detection lag, and upstream-supply-chain consolidation.

FDA's 2026-09-18 Empower letter calls semaglutide/B12 'essentially copies'. The 503B exclusion is still pending. Where the legal channel stands.

FDA rejected the B12 'personalised' workaround on 2026-09-18 and has not finalised the 503B exclusion. What still qualifies under 503A.

Five FDA warning letters dated 2026-08-24, six Lilly retatrutide suits on 2026-08-12, the Empower letter on 2026-09-18. A dated chronology.

Eight failure modes, ranked by how often they appear in public Janoshik data and how hard they are for a buyer to catch before ordering.

Chemyo, Eternal and Chameleon closed between 2026-09-08 and 09-27. What each notice said, what it didn't, and their last COAs on file.

Retatrutide 12 mg: 25.0% at 80 weeks (TRIUMPH-1). Tirzepatide 15 mg: 20.9% at 72 weeks (SURMOUNT-1). No head-to-head trial yet; type 2 diabetes data too.

Retatrutide is not approved. Lilly's expanded access program is the only legal route, and Lilly sued six sellers on 2026-08-12. What that means for buyers.